艾伯维公司（AbbVie）与Iambic生物科技公司达成一项合作协议。根据协议，Iambic将获得一笔前期付款、若干里程碑付款，以及基于合作进展的分级版税收入。
此项合作标志着双方在药物研发领域的深度携手。Iambic不仅将收到首笔预付款项，还有望在达成特定开发、监管及商业化里程碑时，陆续收获额外资金。同时，分级版税机制也为其长期收益提供了保障。
协议的具体条款未完全披露，但这一结构反映出典型的生物技术合作模式——通过分阶段支付来分散风险，同时激励双方推进项目。艾伯维作为大型制药企业，显然看中了Iambic在相关领域的研发潜力；而对Iambic而言，这笔交易不仅输血助力，更是验证其技术平台价值的重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.